ArticleJournal of hepatocellular carcinoma2025
Liver Resection versus Targeted Therapy Plus PD-1 Inhibitors in Hepatocellular Carcinoma with Type I-II Portal Vein Tumor Thrombus: A Comparative Study.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The optimal therapeutic strategy of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is debated. This study aimed to compare the survival outcomes of liver resection (LR) versus targeted therapy plus programmed death-1 (PD-1) inhibitors in HCC patients with PVTT. Patients and Methods: The data of 53 patients with HCC and type I-II PVTT was retrospectively assessed. Among them, 23 underwent LR, and 30 received targeted therapy plus PD-1 inhibitors (TT + PD-1). The baseline characteristics, overall survival (OS) and progression-free survival (PFS) of the two groups were compared. Univariable and multivariable Cox regression analysis were performed to identify independent prognostic factors of OS and PFS. Results: There were no significant differences in baseline characteristics between the LR and TT + PD-1 groups. The LR group showed a significantly superior median OS (27.3 vs 15.3 months; P < 0.001) and PFS (13.8 vs 7.5 months; P = 0.008) compared to the TT + PD-1 group. Multivariable Cox regression analysis identified LR was independently associated with a better OS and PFS. Conclusion: LR may represent an effective therapeutic option for HCC patients with type I-II PVTT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.